BioCryst Pharmaceuticals | Umsatzkosten





Umsatzkosten Veränderung Datum
Alnylam Pharmaceuticals USD 200.15M 57.2M 2025-09
BioCryst Pharmaceuticals USD 12.27M 9.04M 2024-12
Chugai Pharma JPY 87.56B 12.68B 2025-12
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Gilead Sciences USD 1.57B 68M 2025-09
GlaxoSmithKline GBP 2.61B 377M 2025-12
Glaxosmithkline GBP 3.01B 853.01M 2025-09
Incyte USD 121.18M 22.18M 2025-12
Ionis Pharmaceuticals USD 2.34M 1.81M 2025-09
Karyopharm Therapeutics USD 37.43M 2.41M 2024-09
Neurocrine Biosciences USD 264M 252.7M 2025-09
Novavax USD 60.62M 91.77M 2024-09
PTC Therapeutics USD 23.32M 7.83M 2025-09
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sarepta Therapeutics USD 151.45M 1.77M 2025-09
Ultragenyx Pharmaceutical USD 27.99M 4.99M 2025-09
Vertex Pharmaceuticals USD 414.8M 7.3M 2025-09


BioCryst Pharmaceuticals Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.